Atty. Dkt. No. 029318-0981

IN THE UNITED STATES PATING AND TRADEMARK OFFICE

Applicants: Cooper et al.

Title: NOVEL BENZOYL PEROXIDE COMPOSITIONS

Appl. No.: 10/677,857

Filing Date: 10/03/2003

Examiner: Unassigned

Art Unit: 1616

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop MISSING PARTS Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits, within three (3) months of the mailing date of the foreign search report, and within thirty (30) days of receipt of the foreign search report.

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding International application. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner. An English-language counterpart of the foreign-language documents has not been provided. The absence of a translation or an English-language counterpart document does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP§609). English language abstracts are attached.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

FOLEY & LARDNER

Customer Number: 22428

Telephone: Facsimile:

(202) 672-5538

e: (202) 672-5399

Date Jan 5, 2004

Michele M. Simkin Attorney for Applicants Registration No. 34,717

By Mi Sul M Sinly

002.1129148.1

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMER pond to a collection of information unless it contains a valid OMB control Under the Paperwork Reduction Act of 1995, no persons are required to number.

> Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: January 5, 2004

(use as many sheets as necessary)

of Sheet

•	Complete if Known	
Application Number	10/677,857	
Filing Date	10/03/2003	
First Named Inventor	Eugene R. Cooper	
Group Art Unit	1616	
Examiner Name	Unassigned	
Attorney Docket Number	029318-0981	

U.S. PATENT DOCUMENTS						
Examiner Cite No.1	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant	
	- 4 1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
	- 1	<u>-</u>				

Examiner nitials*	Cite No.1	F Office	oreign Patent D	ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	A1	JP	57-26615		GRELAN PHARM. CO. LTD.	02/12/1982		ABS
			7		LTD.			

	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
A2	KIGASAWA ET AL., "Biopharmaceutical Studies of Drug. IV. Studies on Improvement of Dissolution Properties and Gastrointestinal Absorption of 2-oxo-3-[4-(1-oxo-2-isoindolinyl)phenyl]butanamide," DATABASE CA 'Online!, CHEMICAL ABSTRACTS SERVICE, Columbus, Ohio, Database accession no. PREV198274019653, Vol. 101, No. 8, pp. 723-732, XP002261016 (1981).	ABS.
A3	KIGASAWA ET AL., "Biopharmaceutical Studies of Drigs. V. Dissolution Properties and Bioavailability of Ground Mixtures of Poorly Water Soluble Drugs and Soluble Proteins," DATABASE CA 'Online!, CHEMICAL ABSTACTS SERVICE, Columbus, Ohio, Database accession no. 95:156481 CA, Vol. 101, No. 8, XP008024283, Vol. 101, No. 8, pp. 733-739 (1981).	ABS.
	No. ¹	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. KIGASAWA ET AL., "Biopharmaceutical Studies of Drug. IV. Studies on Improvement of Dissolution Properties and Gastrointestinal Absorption of 2-oxo-3-[4-(1-oxo-2-isoindolinyl)phenyl]butanamide," DATABASE CA 'Online!, CHEMICAL ABSTRACTS SERVICE, Columbus, Ohio, Database accession no. PREV198274019653, Vol. 101, No. 8, pp. 723-732, XP002261016 (1981). KIGASAWA ET AL., "Biopharmaceutical Studies of Drigs. V. Dissolution Properties and Bioavailability of Ground Mixtures of Poorly Water Soluble Drugs and Soluble Proteins," DATABASE CA 'Online!, CHEMICAL ABSTACTS SERVICE, Columbus, Ohio, Database accession no. 95:156481 CA, Vol. 101,

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
Standard ST.3). Applicant is to place a check mark here if English language Translation is attached.